Fig 1: PirB promotes reovirus binding and infection.a Domain organization of host proteins used in assays of reovirus receptor binding. The diagram was prepared using BioRender. b Reovirus binding to receptor-expressing cells. CHO cells were transfected with the cDNAs shown and adsorbed with Alexa-647-labeled reovirus T1SA- or T3SA-. Virus-bound cells were quantified by flow cytometry. JAM-A and CAR were used as positive and negative controls, respectively. c Reovirus infection of receptor-expressing cells. Transfected cells expressing the cDNAs shown were adsorbed with T1SA- or T3SA- at a multiplicity of infection (MOI) of 10 or 100 PFU/cell. d Effect of PirB-specific antibody on reovirus binding. PirB-expressing cells were incubated with the concentrations shown of PirA/B-specific monoclonal antibody (mAb) 6C1 or isotype control IgG and adsorbed with Alexa-647-labeled T1SA- or T3SA-. e Effect of PirB-specific antibody on reovirus infection. CHO cells were incubated with mAb 6C1 or isotype IgG and adsorbed with T1SA- or T3SA- (MOI of 50 PFU/cell). f Effect of recombinant PirB ectodomain incubation with virus on reovirus infection. CHO cells were transfected with PirB cDNA or empty vector (EV). T3SA- was incubated with recombinant PirB ectodomain (PirB D1D6) or bovine serum albumin (BSA) prior to adsorption to PirB-expressing CHO cells (MOI of 50 PFU/cell). In c, e, and f, infected cells were quantified using an indirect immunofluorescence assay (IFA). Reovirus binding (b and d) and infectivity (c–f) assays were conducted in quadruplicate and triplicate, respectively. Mean values are shown. Error bars indicate standard deviation (SD).
Fig 2: PirB D3D4 is required for reovirus binding and infectivity.a Schematic of reciprocal exchanges of PirA and PirB ectodomains. PirA (orange) and PirB (blue) have six homologous extracellular Ig-like domains, designated D1 to D6. PirA and PirB extracellular domain sequences were exchanged to yield chimeric receptor constructs. b CHO cells were transfected with the cDNAs shown and scored for reovirus T3SA- binding by flow cytometry. c CHO cells were transfected with the cDNAs shown, absorbed with T3SA- at an MOI of 50 PFU/cell, and scored for infectivity by IFA. Reovirus binding (b) and infectivity (c) assays were conducted in quadruplicate and triplicate, respectively. Mean values are shown. Error bars indicate SD. Statistical analysis was conducted by comparing results of each chimeric receptor with the corresponding parental backbone, which is defined based on the transmembrane and intracellular region. P values were calculated using one-way ANOVA with Turkey’s test. *P < 0.05; **P < 0.01; ****P < 0.0001.
Fig 3: Biophysics of reovirus-PirB interactions.Characterization of reovirus-PirB binding thermodynamics on model surfaces (a–d) and living cells (e–k). a Schematic of quantifying reovirus-PirB interactions using a recombinant PirB-coated model surface. Tips were functionalized with T3SA- virions or recombinant s3. The diagram was prepared using BioRender. b Binding probability on model surfaces with or without PirB-specific mAb treatment. Uncoated surface, nonspecific control. s3-PirB, N = 3; virion-PirB, N = 7; virion-PirB plus mAb, N = 11; uncoating surface, N = 3. c Dynamic force spectroscopy (DFS) plot of the distribution of average rupture forces across eight discrete loading rate ranges. Data corresponding to single and multivalent interactions fit Bell-Evans (solid line) and Williams-Evans models (dotted lines). N = 6605. d Binding probability based on the contact time of reovirus-functionalized tips with a PirB-coated surface. Least-squares fit of the data to a mono-exponential decay model (blue line, r2 of 0.99) provides the average binding kinetic on-rate (kon). N = 5. e Susceptibility of PirB-expressing cells to infection by reovirus virions and ISVPs. Virion, 100 PFU/cell; ISVP, 10,000 ISVPs/cell. N = 3. f Confocal micrograph of PirB-2A-GFP-expressing Lec2 cells. g Representative adhesion map from the boxed area in (f). Reovirus binding is indicated by gray-to-white pixels. In f and g, scale bar, 5 µm. h Reovirus-PirB binding probability using living cells. N = 3. i Adhesion force of reovirus binding to live cells. Virion-PirB, N = 182; virion-PirB plus mAb, N = 140; uncoating surface, N = 93. j DFS plot of prior model surface data (gray) incorporating live-cell data (blue). N = 6605. k Histogram of the force distribution of the live-cell data and a multi-peak Gaussian fit. N = 225. In b–e, h–j, mean values are shown. In b–e, h–j, error bars indicate SD. In b, h, and i, P values were calculated using one-way ANOVA with Turkey’s test. ****P < 0.0001.
Fig 4: PirB is required for efficient T3 reovirus replication and pathogenicity in the murine CNS.a T3 reovirus replication in WT and PirB-/- mice. Mice were inoculated perorally with T3SA- (104 PFU/mouse). N = 11/10/9 at 3/6/9 DPI (WT); N = 9/9/7 at 3/6/9 DPI (PirB-/-). b T3 reovirus replication in the brain of WT and PirB-/- mice. N = 13/13/10 at 2/4/6 DPI (WT); N = 13/10/6 at 2/4/6 DPI (PirB-/-). c T3 reovirus replication in the brain of PirBfl/fl and NspPirB-/- mice. N = 13/19/14 at 2/4/6 DPI (PirBfl/fl); N = 12/9/15 at 2/4/6 DPI (NspPirB-/-). d T3 reovirus virulence in PirBfl/fl and NspPirB-/- mice. e Encephalitis following infection of PirBfl/fl and NspPirB-/- mice. PBS-inoculated PirBfl/fl mice, sham control. Brain inflammation was monitored by MRI at 8 dpi and defined as hyperintensity. Relative level is indicated by hyperintensity voxel percentage. N = 7 (PirBfl/fl); N = 5 (NspPirB-/-); N = 4 (sham). In b–e, mice were inoculated intracranially with T3SA- (25 PFU/mouse). f Reovirus infection of primary cortical neurons is blocked by PirB-specific mAb. Neurons were pre-incubated with mAb or isotype IgG and adsorbed with T3SA+ (100 PFU/cell). g, h T3 reovirus infection of WT and PirB-/- primary neurons. Primary murine cortical neurons were adsorbed with T3SA+ (20 PFU/cell) (g). In f and g, scale bar, 150 µm. Viral titers in tissue (a–c and e) and neuron lysates (h) were determined by plaque assay. In f–h, experiments were conducted in triplicate. WT and PirB-/- mice have comparable tissue weights. In a–c and e, each symbol indicates a single mouse. Mean values are shown. Error bars indicate SD. Statistical analysis: a–c and h, two-way ANOVA with Holm-Sidak’s test; d log-rank (Mantel-Cox) test; e one-way ANOVA with Turkey’s test; f and g two-sided Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Fig 5: CRISPR activation screen identifies PirB as a potential host receptor for reovirus.a Schematic of CRISPRa screening methodology. ? JAM-A-/- x NgR1-/- double-knockout (DKO) MEFs stably expressing dCas9-VP64 were transduced with lentiviruses encoding a murine genome-wide CRISPRa library. Transduced MEFs were serially passaged three times. ? Binding of Alexa-647-labeled reovirus strain T3SA- to transduced DKO MEFs was assessed by flow cytometry. ? The ~ 1% most fluorescent cells were sorted into three populations based on low, medium, and high median fluorescence intensity. ? Genomic DNA from each cell population was analyzed by next-generation sequencing (NGS) to identify corresponding sgRNA sequences. Experiments were conducted using sublibrary A and B. The diagram was prepared using BioRender. b Bioinformatic analysis of screen results. sgRNAs were ranked by read abundance and fold change compared with the input library. Candidate receptor genes encoding proteins with known plasma membrane distribution were selected for validation. Receptor candidate lists of three cell passages of sublibrary A screening are depicted in dot plots. Candidates from low, medium, and high fluorescence intensity sorting are highlighted with light, medium, and dark red colors, respectively.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Mouse PIR-B Protein, CF